1[1]McDonnell PJ,Jacobs MR.Hospital admissions resulting from preventable adverse drug reactions[J].Ann Pharmacother,2002,36:1331-1336.
2[2]Senst BL,Achusim LE,Genest RP,et al.Practical approach to determining costs and frequency of adverse drug events in a health care network[J].Am J Health Syst Pharm,2001,58:1126-1132.
3[3]Wagner JH,Justice AC,Chesney M,et al.Patient and provider-reported adherence:toward a clinically useful approach to measuring antiretroviral adherence[ J ].J Clin Epidemiol,2001,54:S91-98.
4[4]Alcoba M,Cuevas MJ,Perez-Simon MR,et al.Assessment of adherence to triple antiretroviral treatment including indinavir:role of the determination of plasma level of indinavir[J].J Acquir Immune Defic Syndr,2003,33:253-258.
5[5]Urquhart J.The odds of the three nons when an aptly prescribed medicine isn't working:non-compliance,non-absorption,non-response[J].Br J Clin Pharmacol,2002,54:212-220.
6[6]Balkrishnan R.Predictors of medication adherence in the elderly[J].Clin Ther,1998,20:764-771.
7[7]Stone VE,Hogan JW,Schuman P,et al.Antiretroviral regimen complexity,self-reported adherence,and HIV patients understanding of their regimens:survey of women in the HER study[J].J Acquir Immune Defic Syndr,2001,28:124-131.
8[8]Jackevicius CA,Mamdani M,Tu JV.Adherence with statin therapy in elderly patients with and without acute coronary syndromes[J].JAMA,2002,288:462-467.
9[9]Goldman DP,Joyce GF,Escarce JJ,et al.Pharmacy benefits and the use of drugs by the chronically ill[J].JAMA,2004,291:2344-2350.
1Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.Antithrombotic Trialists′ Collaboration. BMJ,2002,324:71-86.
2Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation Ⅲ randomised clinical trial.Lancet,1996,348:633-638.
3Rudd AG, Lowe D, Hoffman A, et al. Secondary prevention for stroke in the United Kingdom: results from the National Sentinel Audit of Stroke.Age Ageing,2004,33:280-286.
4Sappok T, Faulstich A, Stuckert E, et al.Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke, 2001,32:1884-1889.
5Hamann GF, Weimar C, Glahn J, et al.Adherence to secondary stroke prevention strategies results from the German Stroke Data Bank.Cerebrovasc Dis, 2003,15:282-288.
6Wolf PA, Clagett GP, Easton JD, et al.Preventing ischemic stroke in patients with prior stroke and transient ischemic attack : a statement for healthcare professionals from the Stroke Council of the American Heart Association.Stroke,1999,30:1991-1994.
7Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet,2004,364:331-337.
8Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet, 2004,363:2049-2051.
9Stroke Council, American Heart Association; American Stroke Association. Statins after ischemic stroke and transient ischemic attack: an advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke,2004,35:1023.
10Hillen T, Dundas R, Lawrence E, et al. Antithrombotic and antihypertensive management 3 months after ischemic stroke: a prospective study in an inner city population. Stroke, 2000,31:469-475.
